Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Prognostic value of telomere attrition in patients with aplastic anemia.

    ... from patients with critically short telomeres and/or mutation in telomerase genes. The possibility of modulating telomere ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes

    ... mutations, and between severe granulocytic dysplasia and mutation of ASXL1, RUNX1, TP53 and SRSF2 genes. In myeloid neoplasms with ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Aplastic Anemia & MDS International Foundation: Bone marrow failure disease scientific symposium 2012

    ... from patients with critically short telomeres and/or mutation in telomerase genes. The possibility of modulating telomere ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

    ... older persons, detection of an MDS-associated somatic mutation in a cytopenic patient without other evidence of MDS may cause ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes

    ... (VAFs) for founding clone mutations. At least one mutation or cytogenetic abnormality was detected in 83% of the 150 MDS ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Current state of prognostication and risk stratification in myelodysplastic syndromes

    ... SUMMARY: How to best use the results of molecular mutation testing to inform clinical decision making in MDS is still a work ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

    ... shorter OS. Nearly one half of patients (46%) carried a mutation in TP53, DNMT3A, or TET2 and accounted for 64% of deaths. ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

    ... to lenalidomide. It is recommended to identify TP53 mutation early in the disease since it may change the decision regarding ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    ... cells with strong p53 expression confirmed TP53 mutation , whereas cells with moderate expression were predominantly of ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

    ... that there can be no therapeutic benefit, regardless of mutation or cytogenetic subtype, if DNA methyltransferase is not depleted ...

    Research Article last updated 07/20/2018 - 5:15pm.